Meet our advisory board! We are a team of very educated and talented individuals coming together for the benefit of you and your family.
Dr. Robert Dracker, MD, MHA, MBA
Dr. Robert Dracker, a pediatrician, trained hematologist/oncologist, transfusion medicine specialist, and experienced blood and stem cell banking leader, is Americord’s Executive Medical Director and responsible for all of Americord’s laboratory, collection and transport protocols and procedures, licensing and accreditation, establishing quality controls and advising the company with respect to scientific and medical matters.
Dr. Dracker previously served as Executive Medical Director for ViaCord (now ViaCell) until 2007 and Medical Director of Biocyte, the first cord blood company, which also facilitated the first cord blood transplant in the United States, and was the precursor to PharmaStem, whose cord blood collection and processing procedures are still used throughout the industry today. He was also part of the Working Group on Cord Blood Stem Cell Guidelines for New York State and as the Chairperson of the Hematopoietic Progenitor Cell Committee for the NY State Department of Health, an architect of the New York cord blood banking licensing requirements, considered to be the gold standard of cord blood banking accreditations. Dr. Dracker is a graduate of New York University, where he earned his B.A. in Biology, and SUNY Health Science Center at Syracuse, where he earned his Doctorate of Medicine. Dr. Dracker received his M.S. in Health Services Management from New School for Social Research and his M.B.A. from Columbia College.
Martin Smithmyer, MBA
Mr. Smithmyer is Americord’s President and Chief Executive Officer. Prior to founding Americord, he worked in the Healthcare Investment Banking Group at BMO Capital Markets and served as Vice President and Head of Healthcare IT Investment Banking. Mr. Smithmyer held similar healthcare financing positions at Wells Fargo Securities, American Capital (Private Equity) and NewMarket (Venture Capital). Prior to these roles, he was a business development manager at Biomet, one of the largest medical device manufacturers in the U.S. Mr. Smithmyer received an MBA from American University and graduated from the University of Maryland, Baltimore County with a BS in Biology, with an emphasis on pre-med.
Dr. Eric Adler, MD
Dr. Eric Adler is an attending physician in the division of cardiovascular medicine and adjunct faculty member of the Oregon Stem Cell Center at Oregon Health and Science University Hospital. He will assist Americord with operations related to induced pluripotent stem cell (or iPS stem cells) preservation. Dr. Adler’s research, which is funded by the National Institute of Health, has focused on the use of pluripotent stem cells for the study and treatment of cardiovascular disease. His research has been featured in the world’s top scientific journals, including Nature. Previously, Dr. Adler was a cardiologist and stem cell researcher at Mount Sinai Hospital in New York.
Dr. Iffath Hoskins, MD
Dr. Iffath Abbasi Hoskins is a Clinical Associate Professor in the Department of Obstetrics and Gynecology at NYU Langone Medical Center in New York City. She is a practicing obstetrician-gynecologist and a sub-specialist in maternal-Fetal medicine, which focuses on high-risk and complicated pregnancies.
Dr. Hoskins and her colleagues are currently involved in investigations in areas pertaining to maternal and fetal well being, including antepartum fetal heart rate testing, fetal ultrasonography, maternal screening, obstetrical surgical techniques, maternal acid base status, and obstetrical complications including placenta previa. She is also involved in an ongoing investigation in the area of the pathogenesis and diagnosis of chorioamnionitis. Specifically, studying leukocyte and other esterases’ activity for the diagnosis of this infection, the long-term goal being to develop a rapid simple, reliable assay for detecting chorioamnionitis in pregnancy and labor.
Mr. Yahner is a retired Senior Executive of Guidant Corporation. He was instrumental in the spin out and IPO from Guidant’s parent company, Eli Lilly, in 1994. In his career at Guidant, he served as Vice President of Human Resources for the Cardiac Rhythm Management and US Sales Operations divisions. At Lilly, Mr. Yahner was also Vice President of Human Resources for Cardiac Pacemakers, Inc., a subsidiary of Lilly, prior to the IPO. Prior to that assignment he was Director of Operations responsible for human and animal antibiotic fermentation manufacturing and for environmental operations at Lilly’s Tippecanoe Laboratories from 1988 to 1992. He also served in various positions in research, personnel, manufacturing, quality control, and technical services for Lilly. Mr. Yahner joined Lilly in 1971 as an Organic Chemist in the Plant and Animal Sciences division. He holds eight patents and has published articles in several scientific journals. He received an MS degree in Organic Chemistry from Colorado State University.
Timothy P. Fallon
Mr. Fallon is a Director at Merrill Lynch responsible for trading securitized products and is the head of mortgage-backed trading for private wealth management. Previously, he held a similar position at Lehman brothers and D.A. Davison. Mr. Fallon went through Prudential Securities training program. He attended Pennsylvania State University and earned a dual degree in International Business and Marketing.